Oncolytics Biotech (ONCY) Change in Cash (2009 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Change in Cash of -$5.9 million for Q4 2025, down 82.28% year-over-year from -$33.2 million in Q4 2024, and down 221.59% quarter-over-quarter from -$1.8 million in Q3 2025.
Oncolytics Biotech (ONCY) Change in Cash (2009 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Change in Cash for 17 consecutive years, with -$5.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Cash fell 82.28% year-over-year to -$5.9 million; the TTM figure through Dec 2025 stood at -$8.2 million (up 45.4% YoY), while the FY2025 annual figure was -$5.9 million, up 61.63% from the prior year.
- Change in Cash slipped to -$5.9 million in Q4 2025 per ONCY's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Change in Cash topped out at $16.4 million in Q3 2023 and bottomed at -$15.0 million in Q4 2022.
- Historically, Change in Cash has averaged -$1.1 million across 5 years, with a median of -$2.8 million in 2021.
- Annual changes were most pronounced in 2022 — Change in Cash slumped 654.63% — and 2023, when it surged 793.21%.
- Oncolytics Biotech's Change in Cash stood at -$5.1 million in 2021, then plunged by 193.39% to -$15.0 million in 2022, then jumped by 78.58% to -$3.2 million in 2023, then decreased by 0.3% to -$3.2 million in 2024, then tumbled by 82.28% to -$5.9 million in 2025.
- Business Quant data shows ONCY's Change in Cash at -$5.9 million in Q4 2025, -$1.8 million in Q3 2025, and -$70727.8 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.89 Mn |
| Sep 30, 2025 | -1.83 Mn |
| Jun 30, 2025 | -70,727.82 |
| Mar 31, 2025 | -423,725.22 |
| Dec 31, 2024 | -3.23 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Jun 30, 2024 | -3.65 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Dec 31, 2023 | -3.22 Mn |
| Sep 30, 2023 | 16.43 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 3.04 Mn |
| Dec 31, 2022 | -15.04 Mn |
| Sep 30, 2022 | -2.37 Mn |
| Jun 30, 2022 | -5.31 Mn |
| Mar 31, 2022 | -1.01 Mn |
| Dec 31, 2021 | -5.13 Mn |
| Sep 30, 2021 | -3.19 Mn |
| Jun 30, 2021 | 957,759.01 |
| Mar 31, 2021 | 15.48 Mn |